SCHEDULE 13G/A: BlackRock Discloses 7.8% Stake in 4D Molecular Therapeutics

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.8% of 4D Molecular Therapeutics Inc.'s Common Stock as of March 31, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 4 to Schedule 13G, disclosing its beneficial ownership in 4D Molecular Therapeutics Inc.
• As of March 31, 2025, BlackRock, Inc. beneficially owned 3,615,316 shares of 4D Molecular Therapeutics Inc. Common Stock.
• This ownership represents 7.8% of the total outstanding class of securities.
• BlackRock, Inc. holds sole voting power over 3,576,177 shares and sole dispositive power over 3,615,316 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that may beneficially own 5% or greater of the outstanding shares.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it confirms a significant, passive institutional investment by a major asset manager, BlackRock, Inc., in 4D Molecular Therapeutics Inc. This indicates a vote of confidence from a large investor, although the filing itself is a routine disclosure.

Positives

• BlackRock, Inc., a major institutional investor, holds a significant 7.8% stake, indicating substantial institutional confidence in 4D Molecular Therapeutics Inc.
• The filing confirms that BlackRock's acquisition and holding of shares are in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding 4D Molecular Therapeutics Inc.'s future performance or strategic outlook.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Statement from BlackRock, Inc. in Item 10 Certifications)

Industry Context

This filing reflects a routine disclosure by a major asset manager, BlackRock, Inc., regarding its significant passive investment in a biotechnology company, 4D Molecular Therapeutics Inc. Such disclosures are common for large institutional investors managing diverse portfolios across various industries, including the healthcare and biotechnology sectors.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by BlackRock, Inc. may be viewed positively, signaling institutional confidence and potentially contributing to market stability for 4D Molecular Therapeutics Inc.'s stock.

Key Dates

Keywords

BlackRock, 4D Molecular Therapeutics, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, Investment Management